Jonathan Spicer, MD, PhD, McGill University, Montreal, Canada, talks on the growing interest in neoadjuvant and adjuvant approaches in lung cancer. Neoadjuvant nivolumab elicited dramatic responses in a small study of patients with respectable lung cancer in 2018 (NCT02259621), which set off an explosion of clinical trials in this setting. Many trials are underway assessing a range of approaches, including immunotherapy combinations and immunotherapy with chemotherapy. Dr Spicer highlights neoadjuvant therapy as a major focus for research in the coming years, with exciting trials likely to report in the near future. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Dr Spicer reports consultancy for BMS, Merck, AZ, Protalix, Transhit Bio, CLS Therapeutics.
Dr Spicer reports grants from AZ, Roche, Merck, CLS Therapeutics.